DDInter1811 DDInter1658
A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Tinidazole {u} (Compound) resembles {v} (Compound) Metronidazole
Tinidazole {u} (Compound) binds {v} (Gene) CYP3A4
Tinidazole {u} (Compound) upregulates {v} (Gene) FOXO4
Tinidazole {u} (Compound) is included by {v} (Pharmacologic Class) Nitroimidazoles
Tinidazole {u} (Compound) downregulates {v} (Gene) IGFBP2
Tinidazole {u} (Compound) causes {v} (Side Effect) Stevens-Johnson syndrome
Tinidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Tinidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ethambutol
Tinidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Tinidazole {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Tinidazole (Compound) resembles Metronidazole (Compound)
Tinidazole (Compound) binds CYP3A4 (Gene)
Tinidazole (Compound) upregulates FOXO4 (Gene)
Tinidazole (Compound) is included by Nitroimidazoles (Pharmacologic Class)
Tinidazole (Compound) downregulates IGFBP2 (Gene)
Tinidazole (Compound) causes Stevens-Johnson syndrome (Side Effect)
Tinidazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Tinidazole may lead to a major life threatening interaction when taken with Amprenavir